Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)

View Full Paper
Ask AI
Bookmark
Share

Authors

VFVanessa A. FabrizioJSJodi SkilesSKSajad Khazal

Discussion

Loading...

Member takes

Overview

Phase II trial shows 76% event-free survival in NGS-MRD negative B-ALL patients after non-TBI conditioning, highlighting reduced late effects.

Key Points

  • Survival improved with 76% event-free survival noted in patients receiving non-total body irradiation conditioning.
  • Patients enrolled in the trial included 51 individuals, with 82% overall survival achieved at a median follow-up of 2.3 years.
  • Assessments based on next-generation sequencing of minimal residual disease guided choices of myeloablative non-TBI regimens.
  • Graft-versus-host disease was experienced in 39% of patients, indicating a significant post-transplant concern.

Cite This Study

Fabrizio et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfb7https://doi.org/10.1182/blood-2025-163
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial2025
  2. 2Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality2025
  3. 3Safety and feasibility of outpatient myeloablative total marrow and lymphoid Irradiation–based allogeneic transplantation in adults with high-risk acute lymphoblastic leukemia2025
  4. 4Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  5. 5Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting2025